文献速递淋巴瘤

帕博利珠单抗治疗复发或难治性原发纵隔大B细胞淋巴瘤:KEYNOTE-170研究最终分析

Pembrolizumab in relapsed or refractory primary mediastinal large B-cell lymphoma: final analysis of KEYNOTE-170.
PubMed 文献 · Blood · 2023-01-01

KEYNOTE-170为2期研究,评估帕博利珠单抗200 mg每3周方案(最多35周期,约2年)治疗自体干细胞移植后进展或不适合移植的复发/难治性原发纵隔大B细胞淋巴瘤。最终分析中位随访48.7个月,客观缓解率41.5%(完全缓解20.8%,部分缓解20.8%),中位缓解持续时间未达到,4年无进展生存率33.0%,4年总生存率45.3%,安全性可接受。

要点

  • 客观缓解率41.5%,完全缓解与部分缓解各20.8%。
  • 中位缓解持续时间未达到,达到完全缓解者截至数据截止无进展。
  • 中位无进展生存4.3个月,4年无进展生存率33.0%;中位总生存22.3个月,4年总生存率45.3%。

核心结论

  • 随访4年后,帕博利珠单抗在复发/难治性原发纵隔大B细胞淋巴瘤中持续提供持久缓解,长期生存趋势令人鼓舞,安全性可接受。

研究设计与样本

  • 2期KEYNOTE-170研究(NCT02576990),纳入复发/难治性原发纵隔大B细胞淋巴瘤患者,给予帕博利珠单抗200 mg每3周,最多35周期(约2年)。
  • 终点包括研究者按2007年缓解标准评估的客观缓解率、无进展生存和缓解持续时间,以及总生存和安全性。
  • 最终分析中位随访48.7个月(范围41.2-56.2个月)。

主要发现

  • 客观缓解率41.5%,其中完全缓解20.8%,部分缓解20.8%。
  • 中位缓解持续时间未达到;截至数据截止,达到完全缓解的患者无进展。
  • 中位无进展生存4.3个月,4年无进展生存率33.0%;中位总生存22.3个月,4年总生存率45.3%。
  • 截至数据截止,30例患者(56.6%)发生任何级别治疗相关不良事件,最常见为中性粒细胞减少、乏力及甲状腺功能减退。
  • 3/4级治疗相关不良事件发生于22.6%的患者,无5级不良事件。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Previous analyses of the phase 2 KEYNOTE-170 (NCT02576990) study demonstrated effective antitumor activity and acceptable safety of pembrolizumab 200 mg given every 3 weeks for up to 35 cycles (∼2 years) in patients with relapsed/refractory (R/R) primary mediastinal B-cell lymphoma (PMBCL) whose disease progressed after or who were ineligible for autologous stem cell transplantation. The end points included objective response rate (ORR), progression-free survival (PFS), and duration of response (DOR) according to the investigator per 2007 Response Criteria; overall survival (OS); and safety. In this final analysis, median duration of follow-up was 48.7 months (range, 41.2-56.2). The ORR was 41.5% (complete response, 20.8%; partial response, 20.8%). The median DOR was not reached; no patients who achieved a complete response progressed at the data cutoff. The median PFS was 4.3 months; the 4-year PFS rate was 33.0%. The median OS was 22.3 months; the 4-year OS rate was 45.3%. At the data cutoff, 30 patients (56.6%) had any-grade treatment-related adverse events (AEs); the most common were neutropenia, asthenia, and hypothyroidism. Grade 3/4 treatment-related AEs occurred in 22.6% of the patients; no grade 5 AEs occurred. After 4 years of follow-up, pembrolizumab continued to provide durable responses, with promising trends for long-term survival and acceptable safety in R/R PMBCL.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Zinzani PL, Thieblemont C, Melnichenko V, et al. Pembrolizumab in relapsed or refractory primary mediastinal large B-cell lymphoma: final analysis of KEYNOTE-170. Blood. 2023. PMID: 37130017. doi:10.1182/blood.2022019340

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。